Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study

[1]  Shi Yan,et al.  Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial. , 2023, Lung cancer.

[2]  Susan M. Schlenner,et al.  Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. , 2023, Cancer cell.

[3]  F. Bertucci,et al.  CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression , 2022, Cancers.

[4]  L. Sequist,et al.  Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management , 2022, Nature Reviews Clinical Oncology.

[5]  R. Stupp,et al.  Extended resection for potentially operable stage III NSCLC patients after neoadjuvant treatment , 2022, The Journal of Thoracic and Cardiovascular Surgery.

[6]  Jing Zhu,et al.  A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China , 2022, Targeted Oncology.

[7]  M. Tsuboi,et al.  Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. , 2022, Cancer cell.

[8]  R. Aye,et al.  Persistent N2 Following Induction Is Not a Contraindication to Surgery for Lung Cancer. , 2021, The Annals of thoracic surgery.

[9]  D. Olive,et al.  Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity , 2021, Journal for ImmunoTherapy of Cancer.

[10]  M. Tsuboi,et al.  Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA , 2021, Future oncology.

[11]  X. Le,et al.  Dual EGFR/VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  D. Kaufman,et al.  Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity. , 2020, Cell stem cell.

[13]  Haiquan Chen,et al.  Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study. , 2020, The Journal of thoracic and cardiovascular surgery.

[14]  Prasad Adusumilli,et al.  IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  D. Harpole,et al.  Outcomes of surgery versus chemoradiotherapy in patients with clinical or pathologic stage N3 non-small cell lung cancer. , 2019, The Journal of thoracic and cardiovascular surgery.

[16]  A. Drilon,et al.  Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). , 2019, Lung cancer.

[17]  Jun Liu,et al.  Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis , 2019, British medical journal.

[18]  Gregory Riely,et al.  Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. , 2019, JAMA.

[19]  P. Romero,et al.  Navigating metabolic pathways to enhance antitumour immunity and immunotherapy , 2019, Nature Reviews Clinical Oncology.

[20]  Sung Sook Lee,et al.  Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  J. Ahn,et al.  Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. , 2019, Lung cancer.

[22]  Jun S. Liu,et al.  Landscape of B cell immunity and related immune evasion in human cancers , 2018, Nature Genetics.

[23]  B. Han,et al.  Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study , 2018, The oncologist.

[24]  Jia Gu,et al.  fastp: an ultra-fast all-in-one FASTQ preprocessor , 2018, bioRxiv.

[25]  E. Felip,et al.  Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer , 2018, JAMA oncology.

[26]  Xiangdong Wang,et al.  Lung Cancer Heterogeneity and New Strategies for Drug Therapy. , 2018, Annual review of pharmacology and toxicology.

[27]  Geet Duggal,et al.  Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference , 2017, Nature Methods.

[28]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[29]  Jun S. Liu,et al.  Landscape of tumor-infiltrating T cell repertoire of human cancers , 2016, Nature Genetics.

[30]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  Y. Wu,et al.  Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  Yi-long Wu,et al.  Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status , 2015, Journal of Hematology & Oncology.

[33]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[34]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[35]  W. Pao,et al.  Targeted therapies: Afatinib—new therapy option for EGFR-mutant lung cancer , 2013, Nature Reviews Clinical Oncology.

[36]  Y. Yatabe,et al.  Surgery for NSCLC in the era of personalized medicine , 2013, Nature Reviews Clinical Oncology.

[37]  Y. Bae,et al.  CISH is induced during DC development and regulates DC‐mediated CTL activation , 2012, European journal of immunology.

[38]  Laura A. Sullivan,et al.  Molecular and Clinical Aspects of Targeting the VEGF Pathway in Tumors , 2010, Journal of oncology.

[39]  C. Stevens,et al.  Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.

[40]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[41]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Whitton,et al.  Interferon-γ acts directly on CD8+ T cells to increase their abundance during virus infection , 2005, The Journal of experimental medicine.

[43]  S. Karlsson,et al.  Cytokine-Induced Src Homology 2 Protein (Cis) Promotes T Cell Receptor–Mediated Proliferation and Prolongs Survival of Activated T Cells , 2000, The Journal of experimental medicine.

[44]  G. Zimmerman,et al.  P-selectin regulates platelet-activating factor synthesis and phagocytosis by monocytes. , 1995, Journal of immunology.

[45]  B. Halmos,et al.  Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. , 2019, Future oncology.

[46]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[47]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.